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The crystal structure of HIV-l protease with an inhibitor has been compared with the structures of non-viral aspartic proteases complexed with 
inhibitors. In the dimeric HIV-l protease, two 4-stranded /?-sheets are formed by half of the inhibitor, residues 27-29, and the flap from each 
monomer. In the monomeric non-viral enzyme the single flap does not form a/I-sheet with an inhibitor. The HIV-l protease shows more interactions 
with a longer peptide inhibitor than are observed in non-viral aspartic protease-inhibitor complexes. This, and the large movement of the flaps, 
restricts the conformation of the protease cleavage sites in the retroviral polyprotein precursor. 
Retroviral protease; Aspartic protease; Enzyme-substrate interaction; Retroviral polyprotein precursor 
1. INTRODUCTION 
The crystal structure of HIV-l protease (PR) has 
been determined in several laboratories [l-3]. More 
recently, the structure of HIV-l PR complexed with an 
inhibitor has been determined [4] and a second 
cocrystal structure with a different inhibitor is available 
[5]. The catalytically active dimer of retroviral PR is 
structurally similar to the monomeric nonviral aspartic 
proteases which consist of two domains. The PR 
subunit and each domain of the pepsin-like proteases 
have a common structural core consisting of two layers 
of P-sheets with approximately orthogonal directions of 
the chains [2,6-81 and a characteristic distribution of 
the hydrophobic residues which form the hydrophobic 
nucleus of the structure [9]. The interdomain region of 
non-viral aspartic proteases consists of a 6-stranded /3- 
sheet [lo], in contrast to the equivalent intersubunit 
region in the PR dimer which consists of a 4-stranded /3- 
sheet formed by the four termini. The catalytic triplet, 
Asp-Thr-Gly, has a conserved sequence in all retroviral 
and non-viral aspartic proteases [l l] and almost iden- 
tical conformation in all known crystal structures. The 
surface P-hairpin called the flap, residues 42 to 58 of 
HIV-l PR, has the structural and functional analog in 
non-viral aspartic proteases of residues 70 to 83 (pepsin 
numbering). The flap is a flexible structural unit in all 
aspartic proteases; for example, binding of the 
pepstatin fragment o penicillopepsin alters the position 
of the flap’s tig by 2.2 A [12]. The function of the flap, 
by analogy to pepsin-like proteases, is to bind inhibitor 
and possibly also to exclude water from the catalytic 
site. The inhibitor binding interactions in the crystal 
structures of retroviral and non-viral aspartic proteases 
have been compared. 
2. MATERIALS AND METHODS 
The crystal structure of the fungal aspartic protease, rhizopuspep- 
sin, with a reduced peptide inhibitor, D-His-Pro-Phe-His-Phe- 
Q[CHl-NH]-Phe-Val-Tyr, [13] was obtained from the Protein Data 
Bank (3APR). The structure of HIV-l PR is PDB entry 3HVP [2]. 
The complex of HIV-l PR with reduced peptide inhibitor, MVT-101, 
(Ac-Thr-Ile-Nle-t[CHz-NH]-Nle-Gln-Arg-amide, where Nle is 
norleucine and Ki = 780 nM) [4] is PDB 4HVP, while the coordinates 
of a complex with inhibitor JG-365 (Ac-Ser-Leu-Ans-Phe- 
f[CH(OH)CH2N]-Pro-Ile-Val-OMe, with Ki = 0.66 nM for a mix- 
ture of both R and S diastereomers) [13] were provided by Dr. Swain. 
The structures were superimposed on o-carbon atoms using the pro- 
grams, ALIGN [14], or COORDTRANS (R.W. Harrison, unpublish- 
ed), and were examined on an Evans and Sutherland computer 
graphics system using the program, FRODO [15]. 
3. RESULTS AND DISCUSSION 
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In the two cocrystal structures of HIV-l PR [4,5], the 
inhibitor, as proposed from a model complex [7], binds 
in an extended P-conformation with similar interactions 
to those observed in the structures of complexes of non- 
viral aspartic proteases with inhibitors [ 13,16-201. 
There are hydrogen bond interactions to the inhibitor 
provided by residues near the two catalytic triplets, and 
by residues from the flap (residues 74 to 76 in pepsin). 
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Amino acid side chains of peptide-like inhibitors bind 
in successive subsites formed by the protease and con- 
tribute to the specificity of binding. Large hydrophobic 
residues are often found at Pl and Pl ’ in substrates of 
HIV-l PR. Positions P2 to P4 and P2’ to P4’ are less 
selective and can accommodate awide variety of amino 
acid side chains. The binding affinity probably depends 
on the specific combination of side chains, as long as it 
does not interfere with the formation of hydrogen 
bonds to the peptide groups of the substrate. We con- 
sider only the interactions formed to the NH and C = 0 
groups of the peptide-like inhibitors, since these are in- 
dependent of the type of residues forming the inhibitor. 
Table 1 compares these interactions in HIV-l PR and 
the fungal aspartic protease, rhizopus pepsin. In all 
cases, the catalytic aspartic acids (Asp-25 in HIV PR) 
are near the scissile bond between Pl and Pl ’ , and the 
C = 0 of the glycines of the third position in the triplet 
(Gly 27 in HIV PR) accept hydrogen bonds from the in- 
hibitor NH at Pl and P2’ (Fig. la). In addition, the 
fourth residue following the catalytic Asp interacts with 
the NH and C = 0 of P3 in the inhibitor. This residue is 
Asp-29 in HIV PR, and Thr-222 in rhizopus pepsin. 
The interactions of the flap differ in viral and non-viral 
enzymes. 
The most significant differences in the arrangement 
of the ligand binding site in viral and non-viral aspartic 
proteases are due to the more symmetrical environment 
in the retroviral enzyme. There are two flaps in the ac- 
tive dimer of HIV-l PR compared to the single flap in 
non-viral aspartic proteases. Residues in the flap region 
form numerous interactions with the inhibitor in both 
cases, although the flaps are oriented differently in the 
structures of viral compared to non-viral enzymes. In 
Fig. I. (a) A stereo view of the structure of rhizopuspepsin complexed with an inhibitor [13]. Only main chain atoms are shown for residues 37-39, 
220-222 (equivalent to HIV-l PR 27 to 29), and residues 76-82 which form the single flap. The inhibitor P4 to P2’ occupying the subsites is in- 
dicated by thick lines. (b) A stereo view of HIV-l PR complexed with an inhibitor [4] in a similar orientation to Fig. 1. Only main chain atoms 
are shown for clarity. The two &sheets formed by the two flaps, residues 47-54, the inhibitor occupying the subsites P3 to P3’ (thick lines), and 
residues 27-29 near the active site are shown. Residues in the second subunit are indicated by a prime and thin lines. Water is W, and hydrogen 
bond interactions are indicated by dashed lines. 
270 
Volume 269, number 1 FEBS LETTERS August 1990 
Table I 
Potential hydrogen bond interactions between HIV PR or rhizopuspepsin and their inhibitors 
Subsite Substrate atom HIV PR atom Rhizopus pepsin atom 
S4 P4 NH 
P4C=O NH Gly 48’ flap 
s3 P3 NH 0 Asp 291b OH Thr 222 
P3 c=o NH Asp 29’ NH Thr 222 
s2 P2 NH C=O Gly 48’ 0 Asp 19+ flap 
P2 c=o Water 1 NH Gly 78 flap 
Sl Pl NH C=O Gly 27’ C=O Gly 220 *a 
Pl c=o Asp 25 Asp 218 *a 
scissile bond 
Sl’ Pl’ NH Asp 25 ’ Asp 35 *a 
Pl’ c=o Water 1 NH Gly 78 flap 
S2’ P2’ NH C=O Gly 27 C=O Gly 37 *a 
P2’ c=o NH Asp 29 NE Trp 194 
S3’ P3’ NH C=O Gly 48 flap 
P3’ c=o NH Gly 48’ flap 
S4’ P4’ NH 0 Asp 29 + 
Interactions with the NH and C = 0 of the inhibitors [4,5,13,20]. Residues from the two subunits in the HIV PR dimer are distinguished by a prime. 
a The active site triad, Asp-Thr-GIy. 
b 0 atom from the carboxyl side chain of Asp. 
’ This interaction is seen in the structure of Swain et al. 151, and is replaced by a hydrogen bond to a water molecule in the structure of Miller et 
al. [4]. 
the dimer of HIV-l PR, the two flaps lie almost parallel 
to the inhibitor, and form two short P-sheets, one with 
half of the inhibitor (P4 to Pl, and Pl ’ to P3 ‘), and a 
region near the catalytic aspartic acid (residues 27-29) 
(Table I; Fig. lb). The two P-sheets are separated near 
the scissile bond where the two flaps overlap, and there 
are hydrogen bond interactions with a water molecule. 
The main-chain-main-chain hydrogen bonds of the /3- 
sheets formed by PR and the inhibitor extend from P4 
to P3 ’ . A total of 12 hydrogen bond interactions occur 
Fig. 2. Schematic diagram of a PR dimer bound to polyprotein 
substrate. The polyprotein is labeled and shown as two folded regions 
separated by an extended chain around the scissile bond. The PR 
subunits are indicated by I and II, with continuous lines indicating the 
PR dimer structure with substrate bound, and the dashed lines in- 
dicating the PR structure in the absence of substrate. The two flaps 
overlap at one side of the substrate binding region. The scissile bond 
is indicated by two small arrows, and the dashes indicate hydrogen 
bond interactions between the substrate peptide and the PR dimer. 
between the enzyme and the inhibitor NH and C=O 
groups; the flaps are involved in 6 of these, and Gly 27 
to Asp 29 from both subunits provide the other 6 in- 
teractions. 
In the non-viral aspartic proteases, the single flap is 
more perpendicular to the bound inhibitor, and forms 
interactions with Pl to P2’ of the inhibitor. The in- 
teractions with the enzyme extend from P3 to P3 ’ of the 
inhibitor, and involve 2 to 3 hydrogen bond interactions 
with residues of the flap and 3 to 4 additional interac- 
tions with the residues near the catalytic aspartates (Fig. 
la). No P-sheet can be formed as seen in the HIV-l PR, 
and the single flap of pepsin-like proteases contributes 
fewer interactions with the inhibitor than the two flaps 
of HIV-l PR. This difference between HIV and the 
non-viral proteases is consistent with the experimental 
measurement of hydrolysis rates with peptide of dif- 
ferent lengths. In HIV PR, when the substrate, 
SQNYPIV, which extends from P4 to P3 ’ , is shortened 
by one residue on either side, the rate of hydrolysis 
decreases greatly [21]. This indicates that 7 residues is 
the minimal substrate size. Measurements on 
penicillopepsin show a large decrease in catalytic rate 
on removing residues at P3 or P2 ’ which suggests a 
preferred substrate size of at least 5 residues [22]. 
The viral substrate of HIV-l PR is the multi-domain 
polyprotein which consists of folded domains represen- 
ting the individual protein products separated by link- 
ing regions containing the cleavage sites. Comparison 
of the crystal structures of the HIV-PR-inhibitor com- 
plex and the native enzyme suggests that binding of the 
inhibitor changes the relative orientation of the two 
subunits in the dimer by a rotation of about 1.7”, and 
the ends of the flaps move by approximately 7 A [4]. 
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The single flap of pepsin-like proteases does not require 
such a large movement for substrate to enter the bin- 
ding site, and changes of only about 2 A have been 
observed in the structures with and without an in- 
hibitor . 
In the native HIV-l PR dimer the ends of the two 
flaps overlap and form an intersubunit hydrogen bond. 
The overlapping flaps would prevent entry of the 
pol~rotein substrate into the active site. The two flaps 
also overlap in the HIV-l PR complexes with in- 
hibitors, thus ‘pinning’ the inhibitor in the binding 
cleft. Therefore both the binding of substrate or in- 
hibitor to the enzyme, and the release of products re- 
quire a substantial movement of the flaps. Preliminary 
modeling suggests that the flaps must move by about 15 
A from their position in the inhibitor complex in order 
to allow the polyprotein to enter the active site. 
The substantial conformational changes in the en- 
zyme allow more interactions between PR and the 
substrate (Fig. lb), and suggest hat the PR dimer is 
quite flexible in solution. The numerous lig~d-enzyme 
interactions impose a restricted conformation on the 
linker region in the polyprotein precursor and im- 
mobilize the dimeric protease (Fig. 2), providing pro- 
ductive binding. After enzymatic cleavage, each half of 
the substrate is bound only to one monomer, and dimer 
~e~bility can be restored. The large adjacent domains 
in the polyprotein may contribute to the independent 
motion of the monomers facilitating dissociation of the 
enzyme-substrate complex with subsequent release of 
the products. 
In summary, the inhibitor in HIV PR is stabilized by 
additional interactions with the two flexible flaps which 
form two short P-sheets, as opposed to the single flap of 
non-viral proteases. The minimum substrate size is 7 
residues for HIV PR, compared to 5 for pepsin-like 
proteases. This, together with the requirement for a 
substantial motion of the flaps, has consequences for 
the structure of the PR cleavage sites in the retroviral 
polyprotein. The linker region must be sufficiently long 
to enter the PR binding site without undesirable close 
contacts with the rest of the polyprotein. This require- 
ment for about 8-10 residues in a more extended /3- 
conformation may be a significant component of the 
apparent specificity of binding that is not directly 
related to the amino acid sequence around the cleavage 
site. 
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